Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
Mathijs C BunckLennart TonneijckMarcel H A MuskietMark H H KramerIndra C Pieters-van den BosKaruna E W VendrikTrynke HoekstraMarco J BrunoMichaela DiamantDaniël H van RaalteDjuna L CahenPublished in: Diabetes care (2016)
A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected. The long-term clinical consequences of these discrete changes require further study.